Sudan Loganathan
Stock Analyst at Stephens & Co.
(4.24)
# 844
Out of 5,182 analysts
48
Total ratings
63.41%
Success rate
13.46%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATNM Actinium Pharmaceuticals | Reiterates: Overweight | $5 | $1.21 | +313.22% | 3 | Mar 31, 2026 | |
| IMNM Immunome | Maintains: Overweight | $33 → $30 | $23.49 | +27.71% | 4 | Mar 4, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $95 → $100 | $86.68 | +15.37% | 4 | Mar 2, 2026 | |
| APGE Apogee Therapeutics | Initiates: Overweight | $95 | $86.49 | +9.84% | 1 | Dec 17, 2025 | |
| CADL Candel Therapeutics | Reiterates: Overweight | $15 | $6.29 | +138.47% | 2 | Dec 8, 2025 | |
| PYXS Pyxis Oncology | Maintains: Overweight | $5 → $8 | $1.76 | +354.55% | 2 | Nov 24, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $14 → $15 | $10.29 | +45.77% | 3 | Nov 10, 2025 | |
| DCTH Delcath Systems | Maintains: Overweight | $25 → $18 | $10.84 | +66.05% | 4 | Nov 5, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Overweight | $35 | $39.51 | -11.41% | 1 | Oct 28, 2025 | |
| CCCC C4 Therapeutics | Reiterates: Overweight | $6 | $2.83 | +112.01% | 3 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $29.48 | +52.65% | 3 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $16.49 | +81.93% | 4 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $29 → $60 | $44.65 | +34.38% | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $33 | $29.27 | +12.74% | 2 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $8 | $3.76 | +112.77% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $15 | $4.77 | +214.47% | 2 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $100 | $31.54 | +217.06% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.17 | +1,609.40% | 1 | May 14, 2024 |
Actinium Pharmaceuticals
Mar 31, 2026
Reiterates: Overweight
Price Target: $5
Current: $1.21
Upside: +313.22%
Immunome
Mar 4, 2026
Maintains: Overweight
Price Target: $33 → $30
Current: $23.49
Upside: +27.71%
Kymera Therapeutics
Mar 2, 2026
Maintains: Overweight
Price Target: $95 → $100
Current: $86.68
Upside: +15.37%
Apogee Therapeutics
Dec 17, 2025
Initiates: Overweight
Price Target: $95
Current: $86.49
Upside: +9.84%
Candel Therapeutics
Dec 8, 2025
Reiterates: Overweight
Price Target: $15
Current: $6.29
Upside: +138.47%
Pyxis Oncology
Nov 24, 2025
Maintains: Overweight
Price Target: $5 → $8
Current: $1.76
Upside: +354.55%
Arvinas
Nov 10, 2025
Maintains: Overweight
Price Target: $14 → $15
Current: $10.29
Upside: +45.77%
Delcath Systems
Nov 5, 2025
Maintains: Overweight
Price Target: $25 → $18
Current: $10.84
Upside: +66.05%
Centessa Pharmaceuticals
Oct 28, 2025
Initiates: Overweight
Price Target: $35
Current: $39.51
Upside: -11.41%
C4 Therapeutics
Sep 22, 2025
Reiterates: Overweight
Price Target: $6
Current: $2.83
Upside: +112.01%
Sep 9, 2025
Reiterates: Overweight
Price Target: $45
Current: $29.48
Upside: +52.65%
Jul 10, 2025
Reiterates: Overweight
Price Target: $30
Current: $16.49
Upside: +81.93%
Jun 24, 2025
Upgrades: Overweight
Price Target: $29 → $60
Current: $44.65
Upside: +34.38%
Feb 27, 2025
Reiterates: Overweight
Price Target: $33
Current: $29.27
Upside: +12.74%
Feb 24, 2025
Maintains: Overweight
Price Target: $6 → $8
Current: $3.76
Upside: +112.77%
Jan 22, 2025
Reiterates: Equal-Weight
Price Target: $15
Current: $4.77
Upside: +214.47%
May 24, 2024
Reiterates: Overweight
Price Target: $100
Current: $31.54
Upside: +217.06%
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $1.17
Upside: +1,609.40%